King E B, Chew K L, Hom J D, Duarte L A, Mayall B, Miller T R, Neuhaus J M, Wrensch M R, Petrakis N L
Department of Epidemiology, School of Medicine, University of California, San Francisco.
Mod Pathol. 1991 May;4(3):291-6.
To develop a morphometric model of premalignant breast epithelium, we evaluated 120 lesions classified as nonproliferative disease (n = 20), hyperplasia (n = 20), moderate hyperplasia (n = 20), atypical hyperplasia (n = 20), carcinoma in situ (n = 20), and carcinoma (n = 20) in tissue from surgical biopsy or mastectomy. Atypical hyperplasia, a component of duct epithelial proliferative disease, has frequently been described in breasts with carcinoma. Atypical hyperplasia is generally viewed as premalignant or as a marker of increased risk for breast cancer. Measurements of nuclei in breast lesions were obtained with the Leitz TAS Plus on 4-microns sections stained for DNA with the Azure A Feulgen reaction. Nuclei of duct epithelial lesions had morphometric features that displayed changes from nonproliferative disease to carcinoma. The morphometric data from each lesion were compared among the six disease groups. Means of nuclear area, perimeter, maximum and minimum diameter, and large dark and large light intranuclear areas increased with higher degrees of proliferative abnormality. When the six groups of lesions were compared using the means of the first four nuclear features, atypical hyperplasia was significantly different (P less than 0.05) from carcinoma and non-proliferative lesions, but not from hyperplasia, moderate hyperplasia, or carcinoma in situ. These findings suggest that objective morphometric descriptors for characterizing significant proliferative lesions can be established using image cytometry. The progressive increases also suggest that proliferative breast disease is a continuum that includes premalignant lesions.
为了建立癌前乳腺上皮的形态计量学模型,我们评估了120个病变,这些病变来自手术活检或乳房切除术的组织,分类为非增殖性疾病(n = 20)、增生(n = 20)、中度增生(n = 20)、非典型增生(n = 20)、原位癌(n = 20)和癌(n = 20)。非典型增生是导管上皮增殖性疾病的一个组成部分,在患有癌的乳房中经常被描述。非典型增生通常被视为癌前病变或乳腺癌风险增加的标志物。使用Leitz TAS Plus在经Azure A Feulgen反应染色的4微米切片上获取乳腺病变细胞核的测量数据。导管上皮病变的细胞核具有形态计量学特征,这些特征显示出从非增殖性疾病到癌的变化。在六个疾病组之间比较了每个病变的形态计量学数据。核面积、周长、最大和最小直径以及大的深色和大的浅色核内区域的平均值随着增殖异常程度的增加而增加。当使用前四个核特征的平均值比较六组病变时,非典型增生与癌和非增殖性病变有显著差异(P小于0.05),但与增生、中度增生或原位癌无显著差异。这些发现表明,可以使用图像细胞术建立用于表征显著增殖性病变的客观形态计量学描述符。这些渐进性增加还表明,增殖性乳腺疾病是一个连续体,包括癌前病变。